Treatment with ferric carboxymaltose in stable patients with severe iron deficiency anemia in the emergency department
The AABB Choosing Wisely Campaign recommends “don’t transfuse for iron deficiency without hemodynamic instability”. However, the management of iron deficiency anemia (IDA) in the emergency department (ED) is heterogeneous and patients are often over-transfused. Intravenous iron is effective in correcting anemia and new formulations, including ferric carboxymaltose (FCM), allow the administration of high doses with low immunogenicity. The aim of this retrospective study was to analyze the management of hemodynamically stable patients aged 18–55 years with severe IDA (hemoglobin < 8 g/dL), who presented to the ED from January 2014 to July 2018. Patients who received FCM (FCM1) and those who did not receive FCM (FCM0) were compared. Efficacy and safety of FCM at follow-up were evaluated. Seventy-one subjects fulfilled the inclusion criteria (FCM0 n = 48; FCM1 n = 23). The mean Hb at admission was 6.6 g/dL. 40% in the FCM0 and 13% in FCM1 were transfused (p = 0.02). 21% of FCM0 patients were admitted to the ward, while all FCM1 were discharged (p = 0.02). Within 2 weeks, the Hb increase was 2.8 ± 1 g/dL in the FCM1 group. Sixteen FCM1 patients were evaluated at 52 ± 28 days (median 42, range 27–122): the average Hb increase was 5.3 ± 1.4 g/dL. In summary, we showed that FCM administration in the ED in hemodynamically stable patients was associated with fewer transfusions and hospital admissions compared to the FCM0 group; moreover, it succeeded in safely, effectively and rapidly increasing Hb levels after discharge from the ED. Further studies are needed to develop recommendations for IDA in the ED and to identify transfusion thresholds for non-hospitalized patients.
KeywordsSevere anemia Iron deficiency Ferric carboxymaltose Transfusion Choosing wisely
Irene Motta, Giulia Mantovan, Dario Consonni, Nicola Montano and Maria Domenica Cappellini contributed to the study conception and design. Material preparation, data collection and analysis were performed by Giulia Mantovan, Irene Motta and Dario Consonni. Irene Motta, Anna Maria Brambilla, Maria Materia, Marianna Porzio and Margherita Migone De Amicis took care of patients. The first draft of the manuscript was written by Irene Motta and Giulia Mantovan and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Compliance with ethical standards
Conflict of interest
IM received honoraria from Sanofi-Genzyme; NM received honoraria for lecturing from Novo Nordisk; MDC member of Vifor, Sanofi-Genzyme, Celgene, Novartis and Bluebird advisory Board.
Statement of human and animal rights
This study was approved by the Institutional Ethics Committee of our institution.
For this type of study informed consent is not required.
- 1.Kassebaum NJ, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, Regan M, Weatherall D, Chou DP, Eisele TP, Flaxman SR, Pullan RL, Brooker SJ, Murray CJ (2014) A systematic analysis of global anemia burden from 1990 to 2010. Blood 123(5):615–624. https://doi.org/10.1182/blood-2013-06-508325 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, Gernsheimer T, Holcomb JB, Kaplan LJ, Katz LM, Peterson N, Ramsey G, Rao SV, Roback JD, Shander A, Tobian AA (2016) Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA 316(19):2025–2035. https://doi.org/10.1001/jama.2016.9185 CrossRefPubMedGoogle Scholar
- 14.Wang C, Graham DJ, Kane RC, Xie D, Wernecke M, Levenson M, MaCurdy TE, Houstoun M, Ryan Q, Wong S, Mott K, Sheu TC, Limb S, Worrall C, Kelman JA, Reichman ME (2015) Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 314(19):2062–2068. https://doi.org/10.1001/jama.2015.15572 CrossRefPubMedGoogle Scholar
- 16.Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT (2009) Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 49(12):2719–2728. https://doi.org/10.1111/j.1537-2995.2009.02327.x CrossRefPubMedGoogle Scholar
- 17.Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, Chopey IV, Gutzwiller FS, Riopel L, Gasche C, Group FS (2011) FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 141(3):846–853. https://doi.org/10.1053/j.gastro.2011.06.005 CrossRefPubMedGoogle Scholar
- 18.Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Nolen JG, Roger SD, Investigators F-CS (2014) FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transpl 29(11):2075–2084. https://doi.org/10.1093/ndt/gfu201 CrossRefGoogle Scholar
- 19.Kim YW, Bae JM, Park YK, Yang HK, Yu W, Yook JH, Noh SH, Han M, Ryu KW, Sohn TS, Lee HJ, Kwon OK, Ryu SY, Lee JH, Kim S, Yoon HM, Eom BW, Choi MG, Kim BS, Jeong O, Suh YS, Yoo MW, Lee IS, Jung MR, An JY, Kim HI, Kim Y, Yang H, Nam BH, Group FS (2017) Effect of intravenous ferric carboxymaltose on hemoglobin response among patients with acute isovolemic anemia following gastrectomy: the FAIRY randomized clinical trial. JAMA 317(20):2097–2104. https://doi.org/10.1001/jama.2017.5703 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Bisbe E, Garcia-Erce JA, Diez-Lobo AI, Munoz M (2011) A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Anaemia Working Group E Br J Anaesth 107(3):477–478. https://doi.org/10.1093/bja/aer242 CrossRefGoogle Scholar
- 21.Quintana-Diaz M, Fabra-Cadenas S, Gomez-Ramirez S, Martinez-Virto A, Garcia-Erce JA, Munoz M (2016) A fast-track anaemia clinic in the Emergency Department: feasibility and efficacy of intravenous iron administration for treating sub-acute iron deficiency anaemia. Blood Transfus 14(2):126–133. https://doi.org/10.2450/2015.0176-15 CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Shander A, Fink A, Javidroozi M, Erhard J, Farmer SL, Corwin H, Goodnough LT, Hofmann A, Isbister J, Ozawa S, Spahn DR, International Consensus Conference on Transfusion Outcomes G (2011) Appropriateness of allogeneic red blood cell transfusion: the international consensus conference on transfusion outcomes. Transfus Med Rev 25(3):232–246. https://doi.org/10.1016/j.tmrv.2011.02.001 CrossRefPubMedGoogle Scholar
- 26.Quintana-Diaz M, Munoz-Romo R, Gomez-Ramirez S, Pavia J, Borobia AM, Garcia-Erce JA, Munoz M (2017) A fast-track anaemia clinic in the Emergency Department: cost-analysis of intravenous iron administration for treating iron-deficiency anaemia. Blood Transfus 15(5):438–446. https://doi.org/10.2450/2017.0282-16 CrossRefPubMedPubMedCentralGoogle Scholar